Mechanism of action of immunotherapy

Seminars in Oncology

Volumn 41, Issue S5, 2014, Pages S3-S13

  Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; CHEMOKINE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DNA VACCINE; IMMUNOMODULATING AGENT; INTERFERON; IPILIMUMAB; MONOCLONAL ANTIBODY; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; RNA VACCINE; TICILIMUMAB; TUMOR ANTIGEN; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; DRUG MECHANISM; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSURVEILLANCE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); T LYMPHOCYTE ACTIVATION; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 84908309405     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.09.004     Document Type: Article

References (96)

1. M.L. Disis Immune regulation of cancer J Clin Oncol 28 2010 4531 4538
2. O.J. Finn Immuno-oncology: understanding the function and dysfunction of the immune system in cancer Ann Oncol 23 Suppl 8 2012 viii6 viii9
3. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
4. B.L. Kasiske, J.J. Snyder, D.T. Gilbertson, and C. Wang Cancer after kidney transplantation in the United States Am J Transplant 4 2004 905 913
5. L. Le Mire, K. Hollowood, D. Gray, C. Bordea, and F. Wojnarowska Melanomas in renal transplant recipients Br J Dermatol 154 2006 472 477
6. J.I. Herrero De novo malignancies following liver transplantation: impact and recommendations Liver Transpl 15 Suppl 2 2009 S90 S94
7. B. Krynitz, G. Edgren, B. Lindelof, E. Baecklund, C. Brattström, and H. Wilczek Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008 - a Swedish population-based study Int J Cancer 132 2013 1429 1438
8. A. Burgi, S. Brodine, S. Wegner, M. Milazzo, M.R. Wallace, and K. Spooner Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals Cancer 104 2005 1505 1511
9. M. Guiguet, F. Boue, J. Cadranel, J.M. Lang, E. Rosenthal, and D. Costagliola Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study Lancet Oncol 10 2009 1152 1159
10. K. Petoumenos, M.T. van Leuwen, C.M. Vajdic, I. Woolley, J. Chuah, and D.J. Templeton Australian HIV Observational Database. Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD) HIV Med 14 2013 77 84
11. F. Wolfe, and K. Michaud Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study Arthritis Rheum 56 2007 2886 2895
12. L. Zhang, J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, and G. Regnani Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer N Engl J Med 348 2003 203 213
13. J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, and C Lagorce-Pagè Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960 1964
14. C. Jochems, and J. Schlom Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity Exp Biol Med (Maywood) 236 2011 567 579
15. G.P. Dunn, C.M. Koebel, and R.D. Schreiber Interferons, immunity and cancer immunoediting Nat Rev Immunol 6 2006 836 848
16. National Cancer Institute. NCI dictionary of cancer terms: immunotherapy. Available at: www.cancer.gov/dictionary?print=1&cdrid=45729. Accessed April 13, 2014.
17. C.A. Dinarello Historical insights into cytokines Eur J Immunol 37 Suppl 1 2007 S34 S45
18. O.K. Dzivenu, and J. ODonnell-Tormey Cancer and the immune system: the vital connection Cancer Research Institute 2003
19. Proleukin (aldesleukin) [prescribing information]. San Diego, CA: Prometheus Laboratories Inc.; July, 2012.
20. Intron A (interferon alfa-2b, recombinant) [prescribing information]. Whitehouse Station, NJ: Merck; April, 2014.
21. Roferon-A (interferon alfa-2a, recombinant) [prescribing information]. Nutley, NJ: Hoffmann-La Roche Inc; June, 2011.
22. Sylatron (peginterferon alfa-2b) [prescribing information]. Whitehouse Station, NJ: Merck Sharpe & Dohme Corp; December, 2013.
23. P.L. Lollini, F. Cavallo, P. Nanni, and G. Forni Vaccines for tumour prevention Nat Rev Cancer 6 2006 204 216
24. C. Guo, M.H. Manjili, J.R. Subjeck, D. Sarkar, P.B. Fisher, and X.Y. Wang Therapeutic cancer vaccines: past, present, and future Adv Cancer Res 119 2013 421 475
25. A.M. Conforti, D.W. Ollila, M.C. Kelley, G. Gammon, and D.L. Morton Update on active specific immunotherapy with melanoma vaccines J Surg Oncol 66 1997 55 64
26. V.J. Sondak, M.S. Sabel, and J.J. Mule Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res 12 2006 2337s-341s
27. J. Banchereau, and R.M. Steinman Dendritic cells and the control of immunity Nature 392 1998 245 252
28. J. Banchereau, F. Briere, C. Caux, J. Davoust, S. Labecque, and Y.J. Liu Immunobiology of dendritic cells Annu Rev Immunol 18 2000 767 811
29. J.M. Timmerman, and R. Levy Dendritic cell vaccines for cancer immunotherapy Annu Rev Med 50 1999 507 529
30. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma J Clin Oncol 29 2011 330 336
31. C.J. Wheeler, and K.L. Black Vaccines for glioblastoma and high-grade glioma Expert Rev Vaccines 10 2011 875 886
32. Provenge (sipuleucel-T) [prescribing information]. Seattle, WA: Dendreon Corporation; June, 2011.
33. P.W. Kantoff, C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, and D.F. Penson for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
34. R.F. Wang, and S.A. Rosenberg Human tumor antigens for cancer vaccine development Immunol Rev 170 1999 85 100
35. M. Karkada, N.L. Berinstein, and M. Mansour Therapeutic vaccines and cancer: focus on DPX-0907 Biologics 8 2014 27 38
36. E. Neninger Vinageras, A. de la Torre, M. Osorio Rodriguez, M. Catalá Ferrer, I. Bravo, and M. Mendoza del Pino Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer J Clin Oncol 26 2008 1452 1458
37. L. Aurisicchio, and G. Ciliberto Genetic cancer vaccines: current status and perspectives Expert Opin Biol Ther 12 2012 1043 1058
38. C.D. Kaplan, J.A. Krüger, H. Zhou, Y. Luo, R. Xiang, and R.A. Reisfeld A novel DNA vaccine encoding PDGFRβ suppresses growth and dissemination of murine colon, lung and breast carcinoma Vaccine 24 2006 6994 7002
39. R. Xiang, Y. Luo, A.G. Niethammer, and R.A. Reisfeld Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis Immunol Rev 222 2008 117 128
40. M.A. Liu, and J.B. Ulmer Human clinical trials of plasmid DNA vaccines Adv Genet 55 2005 25 40
41. B. Weide, J.P. Carralot, A. Reese, B. Scheel, T.K. Eigentler, and I. Hoerr Results of the first phase I/II clinical vaccination trial with direct injection of mRNA J Immunother 31 2008 180 188
42. B. Weide, S. Pascolo, B. Scheel, E. Derhovanessian, A. Pflugfelder, and T.K. Eigentler Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients J Immunother 32 2009 498 507
43. H. Oshiumi, M. Matsumoto, K. Funami, T. Akazawa, and T. Seya TICAM-1an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction Nat Immunol 4 2003 161 167
44. P.N. Kantoff, T.J. Schuetz, B.A. Blumenstein, L.M. Glode, D.L. Bilhartz, and M. Wyand Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 2010 1099 1105
45. J.L. Gulley, P.M. Arlen, R.A. Madan, K.Y. Tsang, M.P. Pazdur, and L. Skarupa Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer Cancer Immuno Immunother 59 2010 663 674
46. R.J. Amato, R.E. Hawkins, H.L. Kaufman, J.A. Thompson, P. Tomczak, and C. Szczylik Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study Clin Cancer Res 16 2010 5539 5547
47. S. Oudard, O. Rixe, B. Beuselinck, C. Linassier, E. Banu, and J.P. Machiels A phase II study of the cancer vaccine TG-4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings Cancer Immunol Immunother 60 2011 261 271
48. N.N. Sezner, H.L. Kaufman, T. Amatruda, M. Nemunaitis, T. Reid, and G. Daniels Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma J Clin Oncol 27 2009 5763 5771
49. T.J. Harris, and C.G. Drake Primer on tumor immunology and cancer immunotherapy J Immunother Cancer 1 2013 12
50. S.L. Topalian, and S.A. Rosenberg Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans Important Adv Oncol 1990 19 41
51. S.L. Topalian, G.J. Weiner, and D.M. Pardoll Cancer immunotherapy comes of age J Clin Oncol 29 2011 4828 4836
52. M.E. Dudley, J.R. Wunderlich, P.F. Robbins, J.C. Yang, P. Hwu, and D.J. Schwartzentruber Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 2002 850 854
53. M.E. Dudley, J.C. Yang, R. Sherry, M.S. Hughes, R. Royal, and U. Kammula Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens J Clin Oncol 26 2008 5233 5239
54. S.A. Rosenberg, J.C. Yang, R.M. Sherry, U.S. Kammula, M. Highes, and G.Q. Phan Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Clin Cancer Res 17 2011 4550 4557
55. L.A. Johnson, R.A. Morgan, M.E. Dudley, L. Cassard, J.C. Yang, and M.S. Hughes Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 114 2009 535 546
56. G. Gross, T. Waks, and Z. Eshhar Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc Natl Acad Sci U S A 86 1989 10024 10028
57. J.N. Kochenderfer, W.H. Wilson, J.E. Janik, M.E. Dudley, M. Stetler-Stevenson, and S.A. Feldman Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 116 2010 4099 4102
58. D.B. Kohn, G. Dotti, R. Brentjens, B. Savoldo, M. Jensen, and L.J. Cooper CARs on track in the clinic Mol Ther 19 2011 432 438
59. R.A. Morgan, J.C. Yang, M. Kitano, M.E. Dudley, M.C. Laurencot, and S.A. Rosenberg Case report of a serious adverse event following the administration of T cell transduced with a chimeric antigen receptor recognizing ERBB2 Mol Ther 18 2010 843 851
60. R. Brentjens, R. Yah, Y. Bernal, I. Riviere, and M. Sadelain Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial Mol Ther 18 2010 666 668
61. H.E. Heslop Safer CARS Mol Ther 18 2010 661 662
62. M. Bauzon, and T. Hermiston Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy Front Immunol 5 2014 74
63. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
64. R.H. Schwartz Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy Cell 71 1992 1065 1068
65. D.J. Lenschow, T.L. Walunas, and J.A. Bluestone CD28/B7 system of T cell costimulation Annu Rev Immunol 14 1996 233 258
66. C.E. Rudd, A. Taylor, and H. Schneider CD28 and CTLA-4 coreceptor expression and signal transduction Immunol Rev 229 2009 12 26
67. M. Azuma, D. Ito, H. Yagita, K. Okumura, J.H. Phillips, and L.L. Lanier B70 antigen is a second ligand for CTLA-4 and CD28 Nature 366 1993 76 79
68. G.J. Freeman, J.G. Gribben, V.A. Boussiotis, J.W. Mg, V.A. Restivo Jr, and L.A. Lombard Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation Science 262 1993 909 911
69. P.S. Linsley, W. Brady, M. Urnes, L.S. Grosmaire, N.K. Damle, and J.A. Ledbetter CTLA-4 is a second receptor for the B cell activation antigen B7 J Exp Med 174 1991 561 569
70. P.S. Linsley, J.L. Greene, W. Brady, J. Bajorath, J.A. Ledbetter, and R. Peach Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors Immunity 1 1994 793 801
71. E.A. Tivol, F. Borriello, A.N. Schweitzer, W.P. Lynch, J.A. Bluestone, and A.H. Sharpe Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 3 1995 541 547
72. P. Waterhouse, J.M. Penninger, E. Timms, A. Wakeham, A. Shahinian, and K.P. Lee Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4 Science 270 1995 985 988
73. Yervoy (ipilimumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; December, 2013.
74. G.J. Freeman, A.J. Long, Y. Iwai, K. Borque, T. Chernova, and H. Nishimura Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
75. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 2008 677 704
76. M. Terme, E. Ullrich, L. Aymeric, K. Meinhardt, M. Desbois, and N. Delahaye IL-18 induces PD-1-dependent immunosuppression in cancer Cancer Res 71 2011 5393 5399
77. D. Fanoni, S. Tavecchio, S. Recalcati, Y. Balice, L. Vengoni, and R. Fiorani New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas Immunol Lett 134 2011 157 160
78. Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J 11 1992 3887 3895
79. M.E. Keir, S.C. Liang, I. Guleria, Y.E. Latchman, A. Qipo, and L.A. Albacker Tissue expression of PD-L1 mediates peripheral T cell tolerance J Exp Med 203 2006 883 895
80. H. Nishimura, T. Okazaki, Y. Tanaka, K. Nakatani, M. Hara, and A. Matsumori Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice Science 291 2001 319 322
81. H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity 11 1999 141 151
82. T. Okazaki, and T. Honjo PD-1 and PD-1 ligands: from discovery to clinical application Int Immunol 19 2007 813 824
83. H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, and D.B. Flies Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
84. A.T. Parsa, J.S. Waldron, A. Panner, C.A. Crane, I.F. Parney, and J.J. Barry Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma Nat Med 13 2007 84 88
85. Y.E. Latchman, S.C. Liang, Y. Wu, T. Chernova, R.A. Sobel, and M. Klemm PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells Proc Natl Acad Sci U S A 101 2004 10691 10696
86. Y. Zhang, Y. Chung, C. Bishop, B. Daugherty, H. Chute, and P. Holst Regulation of T cell activation and tolerance by PDL2 Proc Natl Acad Sci U S A 103 2006 11695 11700
87. H. Soliman, M. Mediavilla-Varela, and S. Antonia Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer J 16 2010 354 359
88. D.H. Lynch The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer Immunol Rev 222 2008 277 286
89. S.M. Jensen, L.D. Maston, and M.J. Gough Signaling through OX40 enhances antitumor immunity Semin Oncol 37 2010 524 532
90. B.D. Curti, M. Kovacsovics-Bankowski, and N. Morris OX40 is a potent immune-stimulating target in late-stage cancer patients Cancer Res 73 2013 7189 7198
91. A. Hutloff, A.M. Dittrich, K.C. Beier, B. Eljaschewitsch, R. Kraft, and I. Anagnostopoulos ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28 Nature 397 1999 263 266
92. A.H. Sharpe, and G.J. Freeman The B7-CD28 superfamily Nat Rev Immunol 2 2002 116 126
93. hi cells to shift the ratio of effector to regulatory T cells in cancer patients Proc Natl Acad Sci U S A 105 2008 14987 14992
94. R.H. Vonderheide, P.M. LoRusso, M. Khalil, E.M. Gartner, D. Khaira, and D. Soulieres Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells Clin Cancer Res 16 2010 3485 3494
95. X. Fan, S.A. Quezada, M.A. Sepulveda, P. Sharma, and J.P. Allison Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy J Exp Med 211 2014 715 725
96. H. Lu TLR. agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects Front Immunol 5 2014 83